HIV-1 infection
Information
- Disease name
- HIV-1 infection
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05631093 | Active, not recruiting | Phase 3 | A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051) | February 20, 2023 | October 1, 2025 |
| NCT05630755 | Active, not recruiting | Phase 3 | A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052) | February 17, 2023 | October 15, 2025 |
| NCT05052996 | Active, not recruiting | Phase 2 | Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV | October 5, 2021 | November 2027 |
| NCT04776252 | Active, not recruiting | Phase 3 | Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033) | September 15, 2021 | October 15, 2027 |
| NCT04564547 | Active, not recruiting | Phase 2 | Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013] | March 9, 2021 | September 30, 2024 |
| NCT06185452 | Active, not recruiting | Phase 4 | Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine | September 26, 2023 | March 2025 |
| NCT02390297 | Active, not recruiting | Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients | April 2015 | October 2031 | |
| NCT04233879 | Active, not recruiting | Phase 3 | Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020) | February 28, 2020 | March 3, 2025 |
| NCT02859558 | Active, not recruiting | Phase 2 | Early ART to Limit Infection and Establishment of Reservoir | January 2017 | April 30, 2025 |
| NCT00823966 | Completed | Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients | December 2003 | March 2009 | |
| NCT00833781 | Completed | Phase 1/Phase 2 | A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects | August 2009 | December 2013 |
| NCT00849160 | Completed | Phase 3 | Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection. | May 2009 | September 2011 |
| NCT00892437 | Completed | Phase 2 | Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | May 2009 | January 2015 |
| NCT00894114 | Completed | Phase 1 | A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019) | May 2003 | June 2009 |
| NCT00915655 | Completed | Phase 2 | A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents | July 2009 | March 2011 |
| NCT00993148 | Completed | Phase 2 | Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 | May 2010 | April 2013 |
| NCT01000818 | Completed | Phase 1 | A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054) | June 2008 | March 2009 |
| NCT01019044 | Completed | Exploration of HIV Reservoirs | May 2009 | November 2009 | |
| NCT01019551 | Completed | Phase 2 | Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients | September 2010 | February 2013 |
| NCT01082692 | Completed | Phase 1 | Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants | January 2011 | August 2012 |
| NCT01083173 | Completed | Surveillance of Kaletra in Korean Patients | October 2009 | October 2014 | |
| NCT01092104 | Completed | Phase 1/Phase 2 | A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients | February 2009 | November 2009 |
| NCT01097070 | Completed | Phase 2 | A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days | November 2008 | January 2009 |
| NCT01121809 | Completed | Phase 4 | Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily | April 2010 | January 2011 |
| NCT01127464 | Completed | Phase 1 | DCVax Plus Poly ICLC in Healthy Volunteers | May 2010 | November 2012 |
| NCT01213316 | Completed | A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen) | October 2010 | April 2015 | |
| NCT01252940 | Completed | Phase 3 | Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF | November 2010 | October 2014 |
| NCT01266902 | Completed | Phase 3 | A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1 | February 2011 | February 2020 |
| NCT01286259 | Completed | N/A | Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals | January 2011 | May 2014 |
| NCT01286740 | Completed | Phase 2 | Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR | January 2011 | March 2012 |
| NCT01296152 | Completed | Phase 2 | Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women | May 2011 | October 2012 |
| NCT01309243 | Completed | Phase 3 | Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | February 2011 | February 2014 |
| NCT01315353 | Completed | N/A | HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women | April 4, 2012 | February 1, 2017 |
| NCT01319383 | Completed | Phase 1/Phase 2 | The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART | February 2011 | March 31, 2016 |
| NCT01335529 | Completed | Phase 2 | Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin | May 2011 | May 2014 |
| NCT01338883 | Completed | Phase 2 | Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus | June 2011 | June 2013 |
| NCT01348308 | Completed | Phase 3 | Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients | September 2011 | March 2016 |
| NCT01351025 | Completed | Phase 2 | Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells | April 14, 2011 | May 2014 |
| NCT01352117 | Completed | Phase 3 | Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma | November 18, 2011 | November 29, 2018 |
| NCT01352715 | Completed | Phase 3 | Study of Options for Second-Line Effective Combination Therapy (SELECT) | March 13, 2012 | October 29, 2014 |
| NCT01378156 | Completed | Phase 1 | A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART | June 2010 | May 2014 |
| NCT01400412 | Completed | Phase 2 | Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen | January 17, 2012 | June 2014 |
| NCT01403051 | Completed | Phase 2 | High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART | September 2011 | February 2013 |
| NCT01426438 | Completed | Phase 2 | Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate | November 2011 | October 2013 |
| NCT01427738 | Completed | Phase 3 | Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis | June 2011 | January 2014 |
| NCT01435018 | Completed | Phase 3 | Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS | October 1, 2013 | August 29, 2019 |
| NCT01436136 | Completed | N/A | Reducing Cardiovascular Disease (CVD) Risk in HIV on Antiretroviral Therapy Over 12 Months | October 2011 | June 2014 |
| NCT01439841 | Completed | N/A | The Effect of Probiotics in HIV-1 Infection | October 2011 | June 2013 |
| NCT01446718 | Completed | A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years | December 15, 2014 | June 30, 2018 | |
| NCT01453192 | Completed | Phase 3 | Renal Transplantation and Raltegravir in HIV-Infected Patients | December 2011 | November 2015 |
| NCT01466595 | Completed | Phase 2 | Rifaximin as a Modulator of Microbial Translocation and Immune Activation | September 2011 | November 2012 |
| NCT01466985 | Completed | Phase 1 | A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005) | October 21, 2011 | April 10, 2012 |
| NCT01480713 | Completed | Phase 3 | Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors | May 2012 | May 2014 |
| NCT01484522 | Completed | Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth | October 2009 | September 2010 | |
| NCT01492985 | Completed | Phase 2 | Lipopeptide Immunisation With GTU-multiHIV Trial | July 2013 | April 8, 2017 |
| NCT01511809 | Completed | Phase 3 | Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression | September 2010 | May 2015 |
| NCT03859739 | Completed | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002) | April 26, 2019 | May 29, 2020 |
| NCT00323687 | Completed | Phase 4 | SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada | September 2004 | January 2007 |
| NCT00398125 | Completed | Phase 2 | Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults | November 2006 | April 2007 |
| NCT00450580 | Completed | Phase 3 | HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults | March 2007 | August 2008 |
| NCT00481390 | Completed | Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients | June 2007 | December 2007 | |
| NCT00534352 | Completed | Phase 2 | A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment). | January 2008 | March 2009 |
| NCT00552682 | Completed | Phase 3 | Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ | January 2007 | July 2009 |
| NCT00556634 | Completed | Phase 4 | Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual Dosage | April 2006 | January 2008 |
| NCT00743340 | Completed | Phase 2 | Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine | November 22, 2005 | February 13, 2017 |
| NCT02818348 | Completed | Phase 1 | Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients | June 2016 | November 23, 2016 |
| NCT02858401 | Completed | Phase 1 | Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults | January 29, 2015 | February 14, 2019 |
| NCT02887508 | Completed | N/A | HIV Internet Sex Study: Internet-based STI/HIV Prevention for HIV+ Internet Users | December 2010 | November 2014 |
| NCT02906137 | Completed | N/A | Gut-Associated Lymphocyte Trafficking | February 6, 2017 | February 25, 2020 |
| NCT02987530 | Completed | Phase 3 | National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection | April 11, 2017 | January 31, 2020 |
| NCT03001128 | Completed | Biomarkers to Predict Time to Plasma HIV RNA Rebound | February 23, 2017 | January 29, 2021 | |
| NCT03060447 | Completed | Phase 1 | Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers | May 9, 2017 | February 13, 2020 |
| NCT03070223 | Completed | PREPARE (A5361s) Substudy of REPRIEVE (A5332) | February 28, 2017 | August 21, 2023 | |
| NCT03122262 | Completed | Phase 3 | ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy | January 16, 2017 | July 29, 2022 |
| NCT03188523 | Completed | Phase 1 | Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002) | September 8, 2017 | June 4, 2018 |
| NCT03212989 | Completed | Phase 1 | Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART) | June 27, 2017 | July 5, 2022 |
| NCT03272347 | Completed | Phase 2 | Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) | November 27, 2017 | March 9, 2022 |
| NCT03351699 | Completed | Phase 1 | Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002) | January 18, 2018 | November 2, 2018 |
| NCT03405935 | Completed | Phase 3 | Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years | March 1, 2018 | May 29, 2020 |
| NCT03552536 | Completed | Phase 1 | MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) | October 7, 2018 | March 11, 2019 |
| NCT03593187 | Completed | Phase 1/Phase 2 | A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma | January 15, 2019 | July 28, 2020 |
| NCT03631732 | Completed | Phase 3 | Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants | August 28, 2018 | August 19, 2020 |
| NCT03683524 | Completed | Phase 4 | EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS | November 19, 2018 | August 10, 2021 |
| NCT03739866 | Completed | Phase 1 | Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults | November 26, 2018 | June 15, 2020 |
| NCT03743376 | Completed | Phase 2 | The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients | December 12, 2018 | December 31, 2021 |
| NCT03803605 | Completed | Phase 1 | Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons | February 12, 2019 | January 28, 2021 |
| NCT03835546 | Completed | Study to Assess the ART Impact on the Brain Outcomes. The ARBRE Study | October 26, 2015 | June 29, 2018 | |
| NCT03844386 | Completed | Phase 1 | Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults | April 22, 2019 | April 4, 2022 |
| NCT04003103 | Completed | Phase 2 | Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) | September 19, 2019 | November 24, 2022 |
| NCT04133012 | Completed | N/A | Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone | February 10, 2020 | June 9, 2023 |
| NCT04137016 | Completed | N/A | Pilot Study to Assess the Impact of a Mobile Health Application (App) on Clinical Outcomes and Satisfaction of Older HIV-Infected Patients, as an Emerging Tool for Care, Education and Prevention. | December 15, 2016 | July 3, 2018 |
| NCT04233216 | Completed | Phase 3 | Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019) | March 18, 2020 | November 1, 2023 |
| NCT04295772 | Completed | Phase 2 | Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028) | November 26, 2020 | January 25, 2023 |
| NCT04385875 | Completed | Phase 1 | Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study) | June 1, 2020 | February 10, 2022 |
| NCT04568603 | Completed | Phase 1 | Islatravir and Methadone Pharmacokinetics (MK-8591-029) | October 16, 2020 | July 9, 2021 |
| NCT04620304 | Completed | Phase 1 | Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients | January 1, 2021 | May 25, 2022 |
| NCT04802811 | Completed | Phase 1 | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects | March 22, 2021 | November 10, 2021 |
| NCT04811040 | Completed | Phase 1 | Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection | April 8, 2021 | October 17, 2023 |
| NCT05056974 | Completed | Phase 2 | A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs | December 2, 2021 | February 1, 2023 |
| NCT01529749 | Completed | Phase 4 | Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated | February 2012 | February 2016 |
| NCT01543958 | Completed | Phase 2 | Sevelamer for Reducing Endotoxemia and Immune Activation | November 2011 | November 2012 |
| NCT01549119 | Completed | Phase 1/Phase 2 | Phase I/IIa Dose-escalation Clinical Study of VAC-3S | February 2012 | December 2014 |
| NCT01627678 | Completed | Phase 1/Phase 2 | Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART | September 2012 | November 2013 |
| NCT01632891 | Completed | Phase 1/Phase 2 | Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected | January 10, 2014 | June 19, 2016 |
| NCT01637233 | Completed | MARCH Central Nervous System Substudy | June 2012 | December 2015 | |
| NCT01641367 | Completed | Phase 4 | A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure | February 22, 2013 | December 31, 2018 |
| NCT01701895 | Completed | Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera | October 2012 | October 2015 | |
| NCT01704781 | Completed | Phase 1/Phase 2 | Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) | September 2012 | August 2014 |
| NCT01712256 | Completed | Phase 2 | Re-boosting of HIV-1 Infected Subjects With Vacc-4x | December 2012 | January 2014 |
| NCT01714414 | Completed | Phase 2 | A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen | December 2012 | February 2017 |
| NCT01772940 | Completed | Phase 4 | Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting | December 2008 | December 2011 |
| NCT01777997 | Completed | Phase 4 | FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir | April 25, 2013 | February 7, 2017 |
| NCT01894776 | Completed | Phase 1 | A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc | June 2013 | February 2015 |
| NCT01903031 | Completed | Phase 2 | Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART | December 30, 2014 | October 10, 2016 |
| NCT01928407 | Completed | Phase 4 | Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts | February 23, 2011 | January 7, 2013 |
| NCT01928927 | Completed | Phase 2 | Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study) | January 2014 | March 2016 |
| NCT01935089 | Completed | Phase 2 | Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV | August 7, 2013 | May 2, 2016 |
| NCT01950325 | Completed | Phase 1 | VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected... | August 22, 2013 | August 20, 2015 |
| NCT01966822 | Completed | Phase 3 | Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density | January 2014 | October 2015 |
| NCT01969058 | Completed | Phase 2 | Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery | July 2, 2014 | November 2016 |
| NCT01989910 | Completed | Phase 4 | Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients | September 2013 | December 2017 |
| NCT02026752 | Completed | Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay | January 2014 | January 2017 | |
| NCT02042001 | Completed | Phase 4 | Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects | July 1, 2015 | January 15, 2018 |
| NCT02057796 | Completed | Phase 4 | Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 | September 2014 | April 2018 |
| NCT02067767 | Completed | Phase 2 | Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) | February 2014 | December 2015 |
| NCT02089659 | Completed | Phase 1 | A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019) | March 26, 2014 | May 12, 2014 |
| NCT02099474 | Completed | Phase 2 | Evaluation of Raltegravir During the Third Trimester of Pregnancy | June 30, 2014 | April 2017 |
| NCT02116374 | Completed | Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients | December 2014 | June 2016 | |
| NCT02121795 | Completed | Phase 3 | Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF | May 6, 2014 | March 1, 2019 |
| NCT02128217 | Completed | Phase 1 | Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection | May 30, 2014 | May 9, 2017 |
| NCT02155985 | Completed | Phase 2 | Modulation of Immune Activation by Aspirin | August 2014 | July 2015 |
| NCT02157311 | Completed | Phase 3 | 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients | July 2014 | January 2016 |
| NCT02174159 | Completed | Phase 1 | Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003) | September 15, 2014 | July 23, 2015 |
| NCT02211482 | Completed | Phase 4 | Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study | October 2014 | April 2017 |
| NCT02212379 | Completed | Phase 2 | Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL | January 2015 | April 2018 |
| NCT02246998 | Completed | Phase 4 | Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults | December 15, 2014 | February 17, 2016 |
| NCT02264860 | Completed | N/A | Researching Alveolar Macrophage Improvements With Supplements in HIV | October 2014 | December 15, 2018 |
| NCT02273765 | Completed | Phase 3 | Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis | September 11, 2015 | November 28, 2018 |
| NCT02275065 | Completed | Phase 1 | Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants | October 24, 2014 | January 29, 2015 |
| NCT02345226 | Completed | Phase 3 | Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults | January 26, 2015 | January 2, 2019 |
| NCT02345252 | Completed | Phase 3 | Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) | January 26, 2015 | January 9, 2019 |
| NCT02369146 | Completed | Phase 2 | To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults | June 2015 | July 2016 |
| NCT02397096 | Completed | Phase 3 | Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) | June 9, 2015 | September 5, 2023 |
| NCT02397694 | Completed | Phase 2 | Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | March 23, 2015 | February 27, 2019 |
| NCT02412436 | Completed | Phase 2 | PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB | November 3, 2015 | June 15, 2017 |
| NCT02440789 | Completed | Phase 1/Phase 2 | Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART) | December 21, 2015 | February 1, 2018 |
| NCT02446847 | Completed | Phase 2 | 3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption | March 11, 2015 | March 25, 2017 |
| NCT02469246 | Completed | Phase 3 | Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC | June 29, 2015 | March 13, 2019 |
| NCT02473328 | Completed | Phase 2 | Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients | June 2015 | December 2017 |
| NCT02513771 | Completed | Phase 2 | Sitagliptin for Reducing Inflammation and Immune Activation | September 2015 | January 10, 2017 |
| NCT02527096 | Completed | Phase 2 | A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol) | September 17, 2015 | March 2017 |
| NCT02542852 | Completed | Phase 2 | A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia | September 2015 | December 2017 |
| NCT02578706 | Completed | Phase 2 | Targeting Platelets in Chronic HIV Infection | October 2015 | November 2016 |
| NCT02581202 | Completed | The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation | December 21, 2015 | May 27, 2017 | |
| NCT02582684 | Completed | Phase 2 | Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients | December 8, 2015 | September 26, 2017 |
| NCT02588586 | Completed | Phase 2 | A Study of the Safety and Antiretroviral Activity of 3BNC117 | October 2015 | April 2018 |
| NCT02590354 | Completed | N/A | Analytical Treatment Interruption in HIV Positive Patients | January 25, 2016 | June 22, 2018 |
| NCT02592174 | Completed | N/A | Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study | January 26, 2016 | October 27, 2017 |
| NCT02600819 | Completed | Phase 3 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis | December 14, 2015 | October 15, 2019 |
| NCT02603107 | Completed | Phase 3 | Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults | November 20, 2015 | December 23, 2019 |
| NCT02603120 | Completed | Phase 3 | Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed | November 11, 2015 | October 23, 2019 |
| NCT02605954 | Completed | Phase 3 | Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults | November 18, 2015 | January 24, 2018 |
| NCT02607930 | Completed | Phase 3 | Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | November 13, 2015 | July 2, 2021 |
| NCT02607956 | Completed | Phase 3 | Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | November 11, 2015 | July 5, 2021 |
| NCT02611895 | Completed | N/A | Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy | March 2015 | December 31, 2016 |
| NCT02616029 | Completed | Phase 3 | Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I | December 17, 2015 | July 11, 2019 |
| NCT02616783 | Completed | Phase 3 | Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years | December 22, 2015 | March 21, 2018 |
| NCT02629822 | Completed | Phase 2 | Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) | January 14, 2016 | October 28, 2020 |
| NCT02652624 | Completed | Phase 3 | Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women | February 19, 2016 | November 26, 2018 |
| NCT02706717 | Completed | Phase 2 | Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers | April 2016 | August 28, 2017 |
| NCT02707601 | Completed | Phase 3 | Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment | April 1, 2016 | September 29, 2017 |
| NCT02770508 | Completed | Phase 4 | Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects | November 2015 | October 2017 |
| NCT02777229 | Completed | Phase 3 | Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings | July 2016 | July 2021 |
| NCT04406727 | Not yet recruiting | Phase 3 | UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection | December 1, 2023 | June 30, 2026 |
| NCT05705349 | Recruiting | Phase 3 | DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) | March 8, 2023 | November 1, 2026 |
| NCT05582694 | Recruiting | Phase 2 | A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection | July 26, 2023 | December 31, 2025 |
| NCT02881320 | Recruiting | Phase 2/Phase 3 | Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 | September 21, 2016 | December 2024 |
| NCT02486510 | Terminated | Early Phase 1 | Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication | July 2012 | December 2015 |
| NCT02707900 | Terminated | Phase 1 | Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection | March 2016 | July 11, 2018 |
| NCT01153646 | Terminated | Early Phase 1 | Gene Transfer for HIV Using Autologous T Cells | April 2010 | January 2011 |
| NCT02605304 | Terminated | Phase 2 | 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF | February 17, 2016 | March 20, 2017 |
| NCT01130376 | Terminated | Phase 1 | Novel Interventions in HIV-1 Infection | September 2009 | October 2011 |
| NCT00242879 | Terminated | Phase 2 | A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults | August 2005 | June 2007 |
| NCT01353898 | Terminated | Phase 1 | Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003) | June 21, 2011 | January 3, 2012 |
| NCT01489046 | Terminated | Phase 2 | Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive | February 2011 | July 2014 |
| NCT02566707 | Terminated | Phase 2 | Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen | August 2015 | December 2016 |
| NCT04138199 | Terminated | A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation | November 1, 2019 | July 8, 2020 | |
| NCT00709397 | Terminated | HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy | June 2008 | December 2009 | |
| NCT02732457 | Terminated | Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients | September 2014 | February 2015 | |
| NCT01152255 | Terminated | Phase 1 | MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2) | October 2010 | June 2011 |
| NCT01145417 | Terminated | Phase 3 | Pregabalin Trial In HIV Neuropathic Pain | July 2010 | May 2012 |
| NCT02441244 | Terminated | Phase 2 | Probiotic Visbiome for Inflammation and Translocation in HIV Ι | November 15, 2015 | December 19, 2016 |
| NCT02247687 | Terminated | Phase 3 | Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR) | December 2014 | September 2015 |
| NCT03164447 | Unknown status | Phase 2 | UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients | December 2023 | May 2024 |
| NCT01235013 | Unknown status | Phase 4 | Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 | ||
| NCT02370979 | Unknown status | Phase 4 | Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients | February 2015 | July 2017 |
| NCT01874743 | Unknown status | Phase 2 | Rosuvastatin to Decrease Residual Immune Activation in HIV Infection | March 2012 | September 2013 |
| NCT02400021 | Unknown status | Phase 2 | Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals | August 2015 | December 2016 |
| NCT02441231 | Unknown status | Phase 2 | Probiotic Visbiome for Inflammation and Translocation in HIV II | November 2015 | May 2019 |
| NCT04061889 | Unknown status | Clinical Epidemiology Cohort Study for Patient Living With HIV | April 1, 2019 | March 31, 2022 | |
| NCT01017172 | Unknown status | Phase 4 | Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients | November 2009 | March 2010 |
| NCT02557997 | Unknown status | Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation | April 2014 | September 2016 | |
| NCT03588715 | Unknown status | Phase 1 | Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2) | June 18, 2020 | October 30, 2022 |
| NCT05295394 | Withdrawn | Phase 4 | Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study | May 22, 2019 | August 30, 2022 |
| NCT03149211 | Withdrawn | Phase 3 | To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults | April 1, 2025 | December 31, 2025 |
| NCT04041362 | Withdrawn | Phase 2 | the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients | April 2020 | March 2021 |
| NCT01515813 | Withdrawn | Phase 2 | Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation | November 2011 | December 2014 |